SCHEMBL21143804

SCHEMBL21143804

Cc1ccn(-c2nc(Cl)cc(NC3CCC(O)CC3)n2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.43
CDK2 P24941 4/20 0.43
CDC7 O00311 3/20 0.43
CDK1 P06493 3/20 0.43
CDK5 Q00535 3/20 0.43
PIM2 Q9P1W9 3/20 0.43
EGFR P00533 3/20 0.43
JAK2 O60674 3/20 0.43
FLT3 P36888 3/20 0.43
GSK3B P49841 3/20 0.43
JAK3 P52333 3/20 0.43
PRKCQ Q04759 3/20 0.43
IRAK4 Q9NWZ3 3/20 0.43
CLK2 P49760 3/20 0.43
CHEK1 O14757 2/20 0.43
MAPK13 O15264 2/20 0.43
PDPK1 O15530 2/20 0.43
DAPK3 O43293 2/20 0.43
DYRK3 O43781 2/20 0.43
PRKD3 O94806 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127040 1.00 PIM1 (0.43) PIM1CDK2CDC7CDK1CDK5
SCHEMBL21143867 0.88 KCNN3 (0.38) PIM1CDK2CDC7CDK1CDK5
SCHEMBL21143902 0.85 PIM1 (0.42) PIM1CDK2CDC7CDK1CDK5
SCHEMBL31127072 0.85 KCNN3 (0.37) PIM1CDC7CDK1PIM2EGFR
SCHEMBL31127184 0.85 PIM1 (0.42) PIM1CDK2CDC7CDK1CDK5
SCHEMBL21144086 0.85 KCNN3 (0.37) PIM1CDC7CDK1PIM2EGFR
SCHEMBL19686534 0.84 IDH1 (0.48) KCNN2KCNN3
SCHEMBL21143635 0.82 PTGS2 (0.37) KCNN2KCNN3CCNT1
SCHEMBL31127323 0.82 MAPT (0.42) PIM1CDK2CDC7CDK1CDK5
SCHEMBL21144022 0.82 MAPT (0.42) PIM1CDK2CDC7CDK1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 PIM1 3545/4885CDK2 4098/4885CDC7 3353/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 PIM1 3545/4885CDK2 4098/4885CDC7 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.